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Sir,
Maraviroc is a chemokine CCR5 coreceptor antagonist that is cur-
rently used in treatment-experienced R5-tropic HIV-1-infected
patients. Despite the fact that very few data are available on
this new antiretroviral drug in HIV-2 infection, in vitro maraviroc
activity against R5 HIV-2 has very recently been shown.1,2

































Figure 1. Hepatitis C virus (HCV) load and alanine aminotransferase (ALT) levels during and after teicoplanin therapy. Open circles, HCV load. Open
triangles, ALT levels (the horizontal broken line corresponds to the upper level of the normal range).
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is a generally unaddressed issue.3,4 Indeed, as Peterson and
Rowland-Jones5 have recently highlighted, long-term data on
maraviroc HIV-2 treatment are required. In order to provide
insight into this new topic, we report on the long-term successful
control of viral replication, using maraviroc-based salvage com-
bined antiretroviral therapy (cART), in an HIV-2-infected patient.
Herein we report the clinical case of a patient diagnosed
HIV-2 positive in April 2005. At that time, a viral load test was
not available for HIV-2 RNA and the CD4 cell count was
41 cells/mm3 (6%). The patient received a protease inhibitor-
based cART including lopinavir/ritonavir plus abacavir and lamiv-
udine. Also, co-trimoxazole for Pneumocystis jiroveci pneumonia
prophylaxis and valganciclovir for herpes simplex virus prophy-
laxis were prescribed. However, due to intolerance and conse-
quent poor adherence to lopinavir/ritonavir, this was replaced
by atazanavir/ritonavir. Six months later, and despite the persist-
ing poor immunological status [CD4+ cell count of 118 cells/
mm3 (17%)], the HIV-2 RNA was ,200 copies/mL. Nevertheless,
a few months later, the patient experienced treatment failure
[CD4 count of 94 cells/mm3 (15%) and HIV-2 RNA of
87348 copies/mL]. According to the existing knowledge at
the time, the subsequent cART was protease inhibitor double-
boosting with atazanavir and saquinavir. In September 2007, a
genotypic resistance test became available and viral susceptibil-
ity was found to zidovudine, stavudine and tenofovir. Also, resist-
ance mutations for saquinavir and nelfinavir were found. The
selected treatment regimen was zidovudine/lamivudine, tenofo-
vir and indinavir. Eight months later, raltegravir (400 mg twice
daily) plus ritonavir-boosted darunavir (600/100 mg twice daily)
replaced indinavir and, once renal function started declining,
tenofovir was also suspended. According to genotyping analysis,
zidovudine/lamivudine was continued. Further, 1year later, the
viral load was undetectable in spite of low CD4 count mainten-
ance. In May 2009, the patient reported non-specific worsening
of her general condition and poor adherence to the drug
regimen. The HIV-2 viral load was 4275 copies/mL and the
CD4+ count was 111 cells/mm3 (13%). A genotyping test
revealed high-level resistance codons to nucleoside reverse tran-
scriptase inhibitors (Q151M and M184V) and to protease inhibi-
tors (I54M, I64V, L90M, L99F). Even though it was not tested, it
was considered possible that resistance to raltegravir was also
present, given the even lower HIV-2 genetic barrier for this inte-
grase inhibitor. In October 2010, an investigational tropism test
was performed,1 and a combination of tenofovir (325 mg once
daily), boosted darunavir (600/100 mg twice daily) and mara-
viroc (150 mg twice daily) was selected. Presently, the patient
is virologically suppressed (HIV-2 RNA ,40 copies/mL) with a
low but stable CD4 count [CD4¼162 cells/mm3 (15.8%)].
While clinical trials to establish optimal maraviroc doses
in HIV-2 infection are urgently needed, it should be emphasized
that subtherapeutic dosages might promote the selection of
X4 variants, which in HIV-2 infection has been associated
with CD4 depletion, disease progression6 and resistance to
neutralization.7
An understanding of the pharmacokinetic/efficacy relation for
maraviroc in the clinical setting, even in the context of HIV-1 in-
fection, is limited as this drug has only recently become avail-
able. Moreover, maraviroc is a CYP3A4 substrate with high
interpatient variation in its exposure and high potential for
drug–drug interactions; therefore, therapeutic drug monitoring
of this CCR5 antagonist has been advised. Maraviroc antagonist
potency is higher in HIV-1 than in HIV-2, as well as in asymptom-
atic patients as opposed to those with advanced disease.1
Furthermore, CD4 depletion in HIV-2 infection is associated
with a higher frequency of memory CD4 T cells expressing
CCR5.8 This increased resistance in advanced disease might
imply different dosage requirements depending on the disease
stage or dose escalation on a CD4 cell count basis. This argues
for tropism tests along with phenotypic resistance tests and
therapeutic drug monitoring in order to ensure a fully active
maraviroc-based cART. Also, we highlight the need for rando-
mized clinical trial data, to properly guide therapy in HIV-2
infection.
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